Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells

摘要

Objective: Hepatocellular carcinoma (HCC) is the most common liver malignancy. Sorafenib is the first-linesystemic treatment for advanced HCCs. However, due to safety concerns, researchers are now looking for ways to boostthe efficacy of the medication. One approach for reducing toxicity is combining sorafenib with other agents so that alower dose of sorafenib is required. Mesenchymal stromal cells (MSCs) can have an inhibitory effect on HCC tumorgrowth. Mesenchymal Stem Cell-Conditioned Medium (MSC-CM) is the substance extracted from MSC culture andcontains most of the potential cytokines secreted by MSCs. We, therefore, anticipated a synergistic Antitumor Effectof sorafenib in Combination with MSC-CM. In this study, we used HepG2 as our target cell lines. Methods: HepG2cells were treated with sorafenib alone and with sorafenib + MSC-CM. CCK-8 assay was used to evaluate and comparethe inhibition of cell growth between the two groups with different treatments. Results: The combination treatment ofcell lines with sorafenib and MSC-CM had significantly reduced the values of IC50 compared to the use of sorafenibalone (3.4 vs. 2.7 respectively). Conclusion: This study suggests that a combination of sorafenib with MSC-CM cansynergistically suppress the growth of HCC cells.